BHC:TSX-Bausch Health Companies Inc (CAD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | TSX

Last Closing Price

CAD 12.83

Change

-1.33 (-9.39)%

Market Cap

CAD 5.12B

Volume

0.95M

Avg Analyst Target

CAD 34.75 (+170.85%)

Avg User Target

CAD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Bausch Health Companies Inc (BHC) Stock Analysis:
Based on the Bausch Health Companies Inc stock forecasts from 2 analysts, the average analyst target price for Bausch Health Companies Inc is CAD 34.75 over the next 12 months. Bausch Health Companies Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Bausch Health Companies Inc is Slightly Bullish , which is based on 5 positive signals and 4 negative signals. At the last closing, Bausch Health Companies Inc’s stock price was CAD 12.83. Bausch Health Companies Inc’s stock price has changed by -2.58% over the past week, -51.60% over the past month and -64.24% over the last year.

About

Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operat ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-18 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
APHA:CA Aphria Inc

N/A

CAD4.44B 57.08 598.01
WEED:CA Canopy Growth Corporation

-0.36 (-4.77%)

CAD2.97B N/A N/A
TLRY:CA Tilray Inc

-0.41 (-6.23%)

CAD2.94B 46.96 N/A
CRON:CA Cronos Group Inc

-0.27 (-5.91%)

CAD1.72B 46.76 N/A
ACB:CA Aurora Cannabis Inc

-0.24 (-6.06%)

CAD0.84B 1,171.00 N/A
GUD:CA Knight Therapeutics Inc

-0.04 (-0.76%)

CAD0.60B 41.51 8.40
OGI:CA OrganiGram Holdings Inc

-0.17 (-9.83%)

CAD0.50B -99,999.99 N/A
HLS:CA HLS Therapeutics Inc

N/A

CAD0.40B N/A 19.48
INCR-U:CA InterCure Ltd

+0.04 (+0.56%)

CAD0.32B N/A 7.94
TH:CA Theratechnologies Inc

+0.03 (+0.97%)

CAD0.29B 954.70 80.88

ETFs Containing BHC:CA

Symbol Name Weight Mer Price(Change) Market Cap
QHY:CA Mackenzie US High Yield B.. 0.98 % 0.44 %

-2.95 (-3.50%)

CAD0.05B
NHYB:CA NBI High Yield Bond ETF 0.89 % 0.69 %

+0.13 (+0.61%)

CAD0.83B
CJNK SPDR ICE BofAML Broad Hig.. 0.00 % 0.15 %

N/A

CAD0.07B
XFC:CA iShares MSCI Multifactor .. 0.00 % 0.48 %

-0.55 (-2.06%)

CAD0.04B

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -63.28% 9% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -63.28% 9% F 1% F
Trailing 12 Months  
Capital Gain -65.00% 37% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -65.00% 37% F 3% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 5.48% 70% C- 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.48% 70% C- 47% F
Risk Return Profile  
Volatility (Standard Deviation) 31.13% 67% D+ 28% F
Risk Adjusted Return 17.59% 77% C+ 28% F
Market Capitalization 5.12B 100% A+ 83% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 18.74 9% F 3% F
Price / Cash Flow Ratio 3.59 19% F 65% D
EV/EBITDA 15.06 40% F 28% F
Management Effectiveness  
Return on Equity -328.20% 13% F 2% F
Return on Invested Capital 2.02% 87% B+ 43% F
Return on Assets 3.54% 84% B 63% D
Debt to Equity Ratio -21,371.70% 100% A+ 100% A+
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 10.14 31% F 12% F
Short Percent 1.72% 34% F 52% F
Beta 1.60 45% F 20% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector